News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
103 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33091)
2026 (18664)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (1140)
Day
1 (214)
2 (187)
3 (160)
4 (138)
5 (74)
7 (52)
8 (139)
9 (151)
10 (114)
11 (132)
12 (58)
14 (27)
15 (145)
16 (92)
17 (98)
18 (106)
19 (70)
21 (14)
22 (92)
23 (109)
24 (105)
25 (106)
26 (50)
28 (28)
29 (103)
30 (161)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
Day
1
2
3
4
5
7
8
9
10
11
12
14
15
16
17
18
19
21
22
23
24
25
26
28
29
30
Press Releases
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
June 29, 2026
·
7 min read
Mergers & acquisitions
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew.
June 29, 2026
·
2 min read
·
Tristan Manalac
Press Releases
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026
·
7 min read
Press Releases
Novo Nordisk A/S - share repurchase programme - June 29, 2026
June 29, 2026
·
2 min read
Press Releases
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
June 29, 2026
·
6 min read
Press Releases
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
June 29, 2026
·
7 min read
Press Releases
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
June 29, 2026
·
5 min read
Press Releases
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
June 29, 2026
·
4 min read
Press Releases
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
June 29, 2026
·
3 min read
Press Releases
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
June 29, 2026
·
8 min read
Previous
6 of 11
Next
